Article info
Filler
Access to Experimental Drugs in Terminal Illness. Ethical Issues
Citation
Access to Experimental Drugs in Terminal Illness. Ethical Issues
Publication history
- First published April 1, 2000.
Online issue publication
April 01, 2000
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2000 by the Journal of Medical Ethics
Other content recommended for you
- Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society
- Dying individuals and suffering populations: applying a population-level bioethics lens to palliative care in humanitarian contexts: before, during and after the COVID-19 pandemic
- Social determinants of health and slippery slopes in assisted dying debates: lessons from Canada
- Policy implementation analysis on access to healthcare among undocumented immigrants in seven autonomous communities of Spain, 2012–2018
- International palliative care research in the context of global development: a systematic mapping review
- Withholding artificial feeding from the severely demented: merciful or immoral? Contrasts between secular and Jewish perspectives
- Disclosure of terminal illness to patients and families: diversity of governing codes in 14 Islamic countries
- Drawing the line on physician-assisted death
- The case for physician assisted suicide: not (yet) proven
- Meeting information needs of patients with incurable progressive disease and their families in South Africa and Uganda: multicentre qualitative study